Tribendimidine

Tribendimidine is an anthelmintic drug that is used to treat parasitic worm infections. It was developed by the National Institute of Parasitic Diseases in China, and is particularly effective against Ascaris lumbricoides, Clonorchis sinensis, and hookworm infections.

History[edit | edit source]

Tribendimidine was first synthesized in the 1980s by the National Institute of Parasitic Diseases in China. It was developed as part of a program to find new drugs to treat parasitic worm infections, which are a major public health problem in many parts of the world.

Mechanism of action[edit | edit source]

Tribendimidine works by causing paralysis in parasitic worms. It does this by binding to a specific type of neurotransmitter receptor in the worm's nervous system, which disrupts the worm's ability to move and feed. This leads to the death of the worm, which is then expelled from the body.

Uses[edit | edit source]

Tribendimidine is used to treat a variety of parasitic worm infections. It is particularly effective against Ascaris lumbricoides, a type of roundworm that can cause ascariasis; Clonorchis sinensis, a type of liver fluke that can cause clonorchiasis; and hookworms, which can cause hookworm disease.

Side effects[edit | edit source]

Like all drugs, tribendimidine can cause side effects. These can include nausea, vomiting, and abdominal pain. However, these side effects are generally mild and go away on their own after a short time.

Availability[edit | edit source]

Tribendimidine is currently available in China, where it is marketed under the brand name Egaten. It is not currently approved for use in the United States or Europe, but clinical trials are underway to evaluate its safety and effectiveness in these regions.